SETD2 and cancer: Loss of SETD2 is known to create vulnerabilities in some cancers as it decreased levels of the RRM2 ribonucleotide reductase subunit, which can be further reduced by the WEE1 inhibitor, adavosertib, leading to a depletion of the dNTP pool and S phase arrest.42 Similarly, our data showed a 3–8-fold reduction in RRM2 levels with KDM4A knockdown.